| 21/42 | US=65 / Biol/Mol Mueller SC, Artym VV, Kelly T. Invadopodia: interface for invasion. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 403-31. ISBN 978-0-387-69056-8. INVADOPODIA; COMPONENTES MOLECULARES; MEMBRANAS; ATIVIDADE PROTEOLITICA; ACTINA; CORTACTINA; NUCLEOS; PSEUDOPODIA; SALIENCIAS CELULARES EM 3D; INVADOPODIA DEGRADACAO MEDIADA; PROTEASES INVADOPODIAL; MICROAMBIENTE TUMORAL |
| 22/42 | US=65 / Biol/Mol Ragno P, Blasi F. uPAR and proteases in mobilization of hematopoietic stem cells. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 433-50. ISBN 978-0-387-69056-8. |
| 23/42 | US=65 / Biol/Mol Degryse B. The urokinase receptor and integrins constitute a cell migration signalosome. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 451-74. ISBN 978-0-387-69056-8. |
| 24/42 | US=65 / Biol/Mol Zamai M, Malengo G, Caiolfa VR. Measuring uPAR dynamics in live cells. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 475-93. ISBN 978-0-387-69056-8. UPAR; MEDICAO DINAMICA; CELULAS VIVAS; RECEPTORES DE ATIVADOR DE PLASMINOGENIO TIPO UROQUINASE |
| 25/42 | US=65 / Biol/Mol Kopitz C, Krüger A. Janus-Faced effects of Broad-Spectrum and specific MMP inhibition on metastasis. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 495-517. ISBN 978-0-387-69056-8. JANUS-FACED; INIBICAO MMP ESPECIFICA; METASTASE; METASTASE MURINO; INIBICAO DE METALOPROTEINASES |
| 26/42 | US=65 / Biol/Mol Cox JH, Overall CM. Cytokine substrates: MMP regulation of inflammatory signaling molecules. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 519-39. ISBN 978-0-387-69056-8. SUBSTRATOS DE CITOCINAS; MMP; REGULACAO DE MOLECULAS; SINALIZACAO INFLAMATORIAS; INFLAMACAO; QUIMIOCINAS |
| 27/42 | US=65 / Biol/Mol Lynch CC, Matrisian LM. Matrix metalloproteinases as key regulators of tumor-bone interraction. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 541-66. ISBN 978-0-387-69056-8. |
| 28/42 | US=65 / Biol/Mol Christensen IJ, Pappot H, Hoyer-Hansen G. The plasminogen activation system as a source of prognostic markers in cancer. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 569-86. ISBN 978-0-387-69056-8. SISTEMA DE ATIVACAO DO PLASMINOGENIO; MARCADORES; PROGNOSTICO NO CANCER; UPA; UPAR; PAI-1; CANCER DE MAMA; CANCER COLORRETAL; CANCER DE PULMAO; CANCER GINECOLOGICO; CANCER DE PROSTATA |
| 29/42 | US=65 / Biol/Mol Lah TT, Obermajer N, Alonso MBD, Kos J. Cysteine cathepsins and cystatins as cancer biomarkers. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 587-625. ISBN 978-0-387-69056-8. CATEPSINAS; CISTEINA; CISTATINAS; BIOMARCADORES DE CANCER; PEPTIDASES; PESQUISA CLINICA; CARCINOMA DE MAMA; CARCINOMA DE PROSTATA; CARCINOMA DO COLO DO UTERO; CARCINOMA DE OVARIO; CARCINOMA DE PULMAO; CARCINOMA DE COLON; CARCINOMA DE CABECA E PESCOCO; CARCINOMA DA BEXIGA; CARCINOMA DE PANCREAS; CANCER DE FIGADO; CARCINOMA HEPATOCELULAR; MELANOMA; MENINGIOMA; GLIOMA |
| 30/42 | US=65 / Biol/Mol Pennington CJ, Pilgrim S, Span PN, Sweep FC, Edwards DR. Novel degradome markers in breast cancer. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 627-43. ISBN 978-0-387-69056-8. CANCER DE MAMA; MARCADORES DEGRADOME; ASSINATURAS DE EXPRESSAO; PERFIL DE EXPRESSAO DEGRADOME; METALOPROTEINASE POTENCIAL; MARCADORES INIBIDORES |
| 31/42 | US=65 / Biol/Mol Iljin K, Kilpinen S, Ivaska J, Kallioniemi O. Meta-analysis of gene expression microarray data: degradome genes in healthy and cancer tissues. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 645-61. ISBN 978-0-387-69056-8. CANCER; GENES DEGRADOME; META-ANALISE DE DADOS; EXPRESSAO GENICA DE MICROARRAY |
| 32/42 | US=65 / Biol/Mol Laxton R, Ye S. Degradome gene polymorphisms. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 663-77. ISBN 978-0-387-69056-8. GENE DEGRADOME; POLIMORFISMOS; MMP1; MMP2; MMP3; MMP9; MMP12 |
| 33/42 | US=65 / Biol/Mol Frederiksen C, Lomholt AF, Nielsen HJ, Brünner N. TIMP-1 as a prognostic marker in colorectal cancer. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 679-96. ISBN 978-0-387-69056-8. |
| 34/42 | US=65 / Biol/Mol Jacobsen B, Kjaergaard M, Gardsvoll H, Ploug M. Structure and inhibition of the urokinase-type plasminogen activator receptor. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 699-719. ISBN 978-0-387-69056-8. ATIVADOR DO PLASMINOGENIO TIPO UROQUINASE; UPAR; ANTICORPOS MONOCLONAIS; ANTAGONISTAS PEPTIDICOS |
| 35/42 | US=65 / Biol/Mol Stoppelli MP, Andersen LM, Votta G, Andreasen PA. Engineered antagonists of uPA and PAI-1. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 721-58. ISBN 978-0-387-69056-8. UPA; PAI-1; ATIVACAO DO PLASMINOGENIO; DISSEMINACAO DO CANCER; PROPRIEDADES BIOQUIMICAS; ADESAO CELULAR; MIGRACAO CELULAR; INVASAO CELULAR; PROLIFERACAO CELULAR; SOBREVIVENCIA; APOPTOSE; ATIVIDADE ENZIMATICA |
| 36/42 | US=65 / Biol/Mol Fingleton B. MMP inhibitor clinical trials-the past, present, and future. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 759-85. ISBN 978-0-387-69056-8. |
| 37/42 | US=65 / Biol/Mol Nagase H, Murphy G. Tailoring TIMPs for selective metalloproteinase inhibition. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 787-810. ISBN 978-0-387-69056-8. TIMPS; INIBICAO SELETIVA DE METALOPROTEINASE; PROPRIEDADES BIOQUIMICAS |
| 38/42 | US=65 / Biol/Mol Yiotakis A, Dive V. Third-Generation MMP inhibitors: recent advances in the development of highly selective inhibitors. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 811-25. ISBN 978-0-387-69056-8. INIBIDORES DE MMP; GRUPOS DE LIGACAO DE ZINCO; FOSFINICOS; TRANSICAO ANALOGOS |
| 39/42 | US=65 / Biol/Mol Fields GB. Protease-activated delivery and imaging systems. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 827-51. ISBN 978-0-387-69056-8. PROTEASE; SISTEMAS DE IMAGEM; PRO-DROGAS; SISTEMA DE ENTREGA |
| 40/42 | US=65 / Biol/Mol Gill JH, Loadman PM. Development of tumour-selective and endoprotease-activated anticancer therapeutics. In: Edwards D, Hoyer-Hansen G, Blasi F, Sloane BF. The cancer degradome: proteases and cancer biology. New York: Spriger, 2008. p. 853-76. ISBN 978-0-387-69056-8. DESENVOLVIMENTO DE TUMORES SELETIVOS; ENDOPROTEASE ATIVADO; TERAPEUTICA ANTICANCER |